V7B Stock Overview A biotechnology company, develops therapeutic candidates for the treatment of viral diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Assembly Biosciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Assembly Biosciences Historical stock prices Current Share Price US$14.30 52 Week High US$18.00 52 Week Low US$9.07 Beta 0.56 1 Month Change -13.33% 3 Month Change 2.14% 1 Year Change 58.05% 3 Year Change -42.15% 5 Year Change -93.42% Change since IPO -80.16%
Recent News & Updates
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B Dec 26
New minor risk - Market cap size Nov 20 Assembly Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Nov 08
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors At International Herpesvirus Workshop Jul 15 Assembly Biosciences, Inc. announced that it has received $2.77507 million in funding from Gilead Sciences, Inc.
Assembly Biosciences, Inc. Doses First Participant in Phase 1B Clinical Trial Evaluating Next-Generation Capsid Jun 18 See more updates
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B Dec 26
New minor risk - Market cap size Nov 20 Assembly Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Nov 08
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors At International Herpesvirus Workshop Jul 15 Assembly Biosciences, Inc. announced that it has received $2.77507 million in funding from Gilead Sciences, Inc.
Assembly Biosciences, Inc. Doses First Participant in Phase 1B Clinical Trial Evaluating Next-Generation Capsid Jun 18
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor Abi-6250 At the Easl Congress 2024 Jun 06
New minor risk - Insider selling May 02
Assembly Biosciences, Inc., Annual General Meeting, May 29, 2024 Apr 19
Assembly Biosciences, Inc. Appoints Tomas Cihlar to Serve on the Board Dec 08
New major risk - Revenue and earnings growth Nov 10
Assembly Biosciences, Inc. Appoints Anuj Gaggar as Chief Medical Officer Nov 09 Assembly Biosciences Receives Non-Compliance Notice from Nasdaq Oct 01
Assembly Biosciences, Inc. to Present Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting Sep 20
New major risk - Revenue and earnings growth Aug 18
Assembly Biosciences, Inc. Nominates First Herpesvirus Development Candidate ABI-5366, a Long Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes Feb 16
High number of new directors Jan 11
Assembly Biosciences, Inc. Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334 Dec 20
High number of new directors Nov 16
Assembly Biosciences, Inc. Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334 Nov 15
Assembly Biosciences, Inc. Presents New Data at AASLD Liver Meeting Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV Nov 05
High number of new directors Oct 21
Assembly Biosciences, Inc. Announces Executive Changes Oct 07
Assembly Biosciences, Inc. Announces Management Appointments Oct 06 Assembly Biosciences, Inc. Announces Executive Changes
Assembly Biosciences, Inc. to Introduce New Small Molecule Liver-Focused Interferon-a Receptor Agonist Research Program Jun 22
Assembly Biosciences Inc. Initiates Phase 1B Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection Jun 07
High number of new directors Apr 27
Assembly Biosciences, Inc., Annual General Meeting, May 25, 2022 Apr 13
High number of new directors Mar 18
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 12
High number of new directors Feb 04
High number of new directors Nov 24 Assembly Biosciences, Inc.(NasdaqGS:ASMB) dropped from Russell Microcap Growth Index
Assembly Biosciences Presents Data from HBV Core Inhibitor Programs At the International Liver Congress™ EASL 2021 Jun 24
CFO & Principal Accounting Officer Thomas Russo has left the company Jun 05
Full year 2020 earnings released: US$1.75 loss per share (vs US$3.72 loss in FY 2019) Feb 28
Revenue misses expectations Feb 28 Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection
New 90-day low: €4.12 Feb 27
New 90-day high: €5.40 Feb 09
Assembly Biosciences, Inc. Announces Board Changes, Effective December 31, 2020 Dec 10 Assembly Biosciences, Inc. Appoints Nicole S. White as Senior Vice President of Pharmaceutical Development and Manufacturing
New 90-day low: €4.20 Nov 07
Third quarter 2020 earnings released: US$0.094 loss per share Nov 07
Revenue beats expectations Nov 07
Assembly Bio Provides Update on the Ongoing Phase 2 Extension Study of Vebicorvir in Patients with Chronic Hepatitis B Virus Infection Nov 06
Assembly Biosciences, Inc. Announces HBV Core Inhibitor Research and Development Program Nov 04
New 90-day low: €12.60 Oct 10
New 90-day low: €13.80 Sep 24
New 90-day low - €16.50 Sep 03
First half earnings released Aug 06
New 90-day high - €23.40 Jul 21 Shareholder Returns V7B DE Biotechs DE Market 7D 0% 2.3% 0.3% 1Y 58.0% -12.8% 6.9%
See full shareholder returns
Return vs Market: V7B exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is V7B's price volatile compared to industry and market? V7B volatility V7B Average Weekly Movement n/a Biotechs Industry Average Movement 7.6% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: V7B's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine V7B's volatility change over the past year.
About the Company Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV).
Show more Assembly Biosciences, Inc. Fundamentals Summary How do Assembly Biosciences's earnings and revenue compare to its market cap? V7B fundamental statistics Market cap €97.93m Earnings (TTM ) -€39.22m Revenue (TTM ) €27.22m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) V7B income statement (TTM ) Revenue US$28.33m Cost of Revenue US$52.66m Gross Profit -US$24.33m Other Expenses US$16.47m Earnings -US$40.80m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -6.42 Gross Margin -85.90% Net Profit Margin -144.05% Debt/Equity Ratio 0%
How did V7B perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/31 15:32 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Assembly Biosciences, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Skorney Baird Raymond Deacon Brean Capital Madhu Kumar B. Riley Securities, Inc.
Show 12 more analysts 
